anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Diabetic kidney disease (DKD) has become the primary cause of end-stage renal disease (ESRD), causing an urgent need for preventive strategies for DKD. Astragaloside I (ASI), a bioactive saponin extracted from Astragalus membranaceus (Fisch.) Bunge has been demonstrated to possess a variety of biological activities. This study investigates the therapeutic potential of ASI in DKD and the underlying molecular mechanism using db/db mice in vivo and high glucose (HG)-induced SV40-MES-13 cells in vitro. The results indicated that ASI significantly ameliorated renal dysfunction and mitigated the pathological alterations in the renal tissues of db/db mice. Moreover, ASI was found to reduce the levels of renal fibrosis makers and suppress the activation of TGF-β1/Smad2/3 pathway in both db/db mice and HG-induced SV40-MES-13 cells. Furthermore, ASI downregulated HDAC3 expression, upregulated Klotho expression, and enhanced Klotho release. ASI is directly bound to HDAC3, and the beneficial effects of ASI on Klotho/TGF-β1/Smad2/3-mediciated renal fibrosis in DKD were reversed by the HDAC3 agonist ITSA-1. In conclusion, ASI attenuates renal fibrosis in DKD, and may act through concurrently inhibiting HDAC3 and TGF-β1, thereby regulating HDAC3-mediciated Klotho/TGF-β1/Smad2/3 pathway.
Chronic temporomandibular disorder (cTMD) as a term based on the diagnostic criteria for temporomandibular disorders (DC/TMD) classification refers, in this paper, to the condition listed that has a non-mechanical association without any obvious organic cause. Specifically, this is the condition that falls under the International Classification of Diseases 11th revision (ICD-11) classification of chronic primary and chronic secondary pains. This implies that there is increased responsiveness of nociceptive neurons in the central nervous system, a phenomenon known as central sensitisation. cTMD patients may have their beginning with genetic susceptibility to pain. Although no single gene is exclusively linked to cTMD, various genes associated with nervous and musculoskeletal systems are believed to play a role. Environmental triggers and epigenetic changes are also thought to contribute to cTMD development. The biopsychosocial model emphasises the need to comprehensively address biological, psychological and social factors in cTMD assessment and management. In this study, we leverage the cyclic causation framework within the biopsychosocial model to illuminate the intricate interplay between biological and psychosocial factors in the context of cTMD. The conceptualisation of cTMD involves the dynamic evolution of genetic predispositions, influenced by life events and other biological susceptibilities. These factors collectively contribute to the emergence of nociplastic changes, ultimately manifesting as the distinctive features observed in individuals afflicted with cTMD.
A person diagnosed with Multiple Sclerosis and spasticty of one lower extremity. The person must be able to walk 25 feet and cannot have had Botox in the lower extremity on the last 6 months.
Participants Forty children with spastic CP between the ages of 5 and 11 years were enrolled in this study. Children were classified according to the Gross Motor Function Classification System. The patients were randomized and divided into 2 groups of 20 people. A randomized list is prepared in a computer environment by a statistician for randomization. In this list, the odd numbers for the control group and the MT group were given double numbers. The group identification is printed on sequentially numbered cards placed in sealed envelopes. After enrollment, the numbered envelope was opened by the patient and the blind investigator. The researcher started the session by placing the proper disc CD player before the beginning of the work. Children from 5 to 11 years of age, who had a spastic type CP diagnosis and were able to understand the commands as co-operative, with no hearing problems between GMFCS levels I and III were included in the study. Acute and chronic infectious diseases, coagulation diseases, progressive cerebral diseases such as neoplasms, inherited diseases such as trisomy 21 syndrome, hearing loss, surgery from the upper and lower extremity in the last 1 year, psychiatric problems, weak cooperatives were excluded from the study.

Study design Neurodevelopmental therapy was applied in the first group music accompaniment and only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes. Classical music is preferred as a musical style. The exercises performed in the musical accompaniment are made according to the rhythms in the music. The treatment schedule is planned so that the commands given to the illness and the movements required to be removed are made in the presence of rhythms. The age and body mass index (BMI) of all patients were recorded. Children were evaluated with Gross Motor Function Measurement (GMFM-88), WeeFIM for functional independence measurement, Wong-Baker faces pain rating scale (FACES) for pain intensity before, at the end of treatment and after 3 months of treatment. Outcome measures are described in more detail below. According to the power analysis results, when the number of enough participants was reached, the study was stopped. Ethics committee approval for the study was obtained from the Istanbul Science University Ethics Committee for Clinical Researches.
MOTIVATION: Multi-trait analysis has been shown to have greater statistical power than single-trait analysis. Most of the existing multi-trait analysis methods only work with a limited number of traits and usually prioritize high statistical power over identifying relevant traits, which heavily rely on domain knowledge.
RESULTS: To handle diseases and traits with obscure etiology, we developed TraitScan, a powerful and fast algorithm that identifies potential pleiotropic traits from a moderate or large number of traits (e.g. dozens to thousands) and tests the association between one genetic variant and the selected traits. TraitScan can handle either individual-level or summary-level GWAS data. We evaluated TraitScan using extensive simulations and found that it outperformed existing methods in terms of both testing power and trait selection when sparsity was low or modest. We then applied it to search for traits associated with Ewing Sarcoma, a rare bone tumor with peak onset in adolescence, among 754 traits in UK Biobank. Our analysis revealed a few promising traits worthy of further investigation, highlighting the use of TraitScan for more effective multi-trait analysis as biobanks emerge. We also extended TraitScan to search and test association with a polygenic risk score and genetically imputed gene expression.
AVAILABILITY AND IMPLEMENTATION: Our algorithm is implemented in an R package "TraitScan" available at https://github.com/RuiCao34/TraitScan.
A pharmaceutical composition for the treatment of rheumatism and a method of preparing it are provided. The composition consists of an alcoholic extract of 1-4 parts by weight  Tripterygium hypoglaucum  (Levl.) Hutch.; 1-4 parts by weight  Epimedium brevicornum  Maxim.; 1-4 parts by weight  Lycium barbarum  L.; and 1-4 parts by weight  Cuscuta chinensis  Lam., or  Cuscuta australis  R. Br. The composition has substantial therapeutic efficacy, with mild side effects, and is easy to administer.
FIELD: medicine. SUBSTANCE: medicinal agent is applied on the damaged skin surface or mucous tissue. Agent has the dissolved peptides, amino acids and mineral compounds obtained by freezing the milled animal raw at -18 C (not above) for 10-90 days. Then raw is defrozen and immersed in 1% glacial acetic acid aqueous solution at ratio = 1:1 by weight for 8-12 h at 18-25 C at periodic stirring. Then solution is poured off from mass and washed off up to pure water. The prepared mass is treated again with weak organic acid at 54-60 C, at pH = 4.6-4.8 at ratio = 1:1 by mass, for 30-40 min and the dissolved active peptides, amino acids and mineral substances were extracted, centrifuged, fatty is removed and solvent is filtered. The prepared substrate is defrozen, treated with weak organic acid, the dissolved active peptides, amino acids and mineral compounds were extracted, centrifuged, fatty is removed and filtered. The prepared substrate is used as gel or subjected for lyophilic drying and used as powder for wound surfaces, burns, trophic ulcers and other damages treatment. EFFECT: improved method of treatment.
ETHNOPHARMACOLOGICAL RELEVANCE: Endometriosis (EMS) is a common gynecological disease that causes dysmenorrhea, chronic pelvic pain and infertility. Luoshi Neiyi Prescription (LSNYP), a traditional Chinese medicine (TCM) formula, is used to relieve EMS in the clinic.
AIMS: This study aimed to examine the active components of LSNYP and the possible mechanism involved in its treatment of EMS.
MATERIALS AND METHODS: Ultrahigh-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF-MS) was used to identify the chemical components of LSNYP. Human primary ectopic endometrial stromal cells (ecESCs) and eutopic endometrial stromal cells (euESCs) were isolated, and the expression levels of hypoxia inducible factor 1A (HIF1A), enhancer of zeste homolog 2 (EZH2) and steroidogenic factor 1 (SF-1) were detected by immunofluorescence and qPCR. Cobalt chloride (CoCl2) was utilized to construct an in vitro hypoxic environment, and lentiviruses were engineered to downregulate HIF1A and EZH2 and upregulate EZH2. Subsequently, the expression levels of HIF1A, EZH2, and SF-1 were measured using qPCR or western blotting. The binding of EZH2 to the SF-1 locus in ESCs was examined via ChIP. Furthermore, the effects of LSNYP on the HIF1A/EZH2/SF-1 pathway were evaluated both in vitro and in vivo.
RESULTS: A total of 185 components were identified in LSNYP. The protein and gene expression levels of HIF1A and SF-1 were increased, whereas those of EZH2 were decreased in ecESCs. After treating euESCs with 50 μmol L-1 CoCl2 for 24 h, cell viability and estradiol (E2) production were enhanced. Hypoxia decreased EZH2 protein expression, while si-HIF1A increased it. SF-1 was increased when EZH2 was downregulated in normal and hypoxic environments, whereas the overexpression of EZH2 led to a decrease in SF-1 expression. ChIP revealed that hypoxia reduced EZH2 binding to the SF-1 locus in euESCs. In vitro, LSNYP-containing serum decreased E2 and prostaglandin E2 (PGE2) production, inhibited cell proliferation and invasion, and reduced the expression of HIF1A, SF-1, steroidogenic acute regulatory protein (StAR), and aromatase cytochrome P450 (P450arom). In vivo, LSNYP suppressed inflammation and adhesion and inhibited the HIF1A/EZH2/SF-1 pathway in endometriotic tissues.
CONCLUSIONS: LSNYP may exert pharmacological effects on EMS by inhibiting E2 synthesis and inflammation through regulation of the HIF1A/EZH2/SF-1 pathway. These results suggest that LSNYP may be a promising candidate for the treatment of EMS.
INTRODUCTION: Ubiquitin C-terminal hydrolase L1 (UCHL1) has been associated with a severe, complex autosomal recessive spastic paraplegia (HSP79) [1] [2] [3] [4]. More recently, UCHL1 loss of function (LoF) variants have been associated to an autosomal dominant disease characterized by late-onset spastic ataxia, neuropathy, and frequent optic atrophy [5].
METHODS: Routine clinical care whole-genome (WGS) and exome (ES) sequencing.
RESULTS: We present three families with autosomal dominant UCHL1-related disorder. The clinical phenotype mainly associated optic atrophy, mixed cerebellar and sensory ataxia, and possible hearing loss. We delineated two major phenotypes, even within the same family: (1) juvenile severe optic atrophy followed by a later-onset ataxia, or (2) late-onset ataxia with asymptomatic or mild optic atrophy. The families harboured three novel heterozygous variants in UCHL1: two loss of function (p.Lys115AsnfsTer40; c.171_174 + 7del11), and one missense (p.Asp176Asn) involving the catalytic site of the protein and potentially altering the adjacent splice site.
DISCUSSION: We confirm the existence of dominantly inherited UCHL1 pathogenic variants. We describe a considerable intrafamilial phenotypic variability, with two main phenotypes. Optic atrophy was consistently present, but with varying degrees of severity. Neither delayed motor or intellectual development, nor dysmorphic features were part of the dominant phenotype in comparison with the autosomal recessive form. The molecular mechanism appears to be haploinsufficiency. UCHL1 monoallelic variants should therefore be considered in any case of early-onset optic atrophy or in late-onset complex ataxic syndrome with asymptomatic optic atrophy.
Patients undergo six 1-hour sessions twice a week for 3 weeks with a trained counselor in which they choose up to 3 books on CD and listen to the book and/or discuss their impressions and thoughts about the contents with the counselor. Patients are provided with a portable CD player to listen to the books during their hospitalization.
The present invention relates to the field of genetic engineering, and discloses DNA of PhiX174 phage E gene obtained after gene mutation. The serial number of the DNA is shown as SEQ ID NO:1. The invention also discloses a preparation method of the DNA, a punching plasmid vector containing the DNA and application thereof in the preparation of a vaccine. The expression quantity of mutant phage E gene of the present invention in poultry salmonella is much higher than that of conventional phage E gene in poultry salmonella. Compared with the conventional phage E gene, cleavage rate of the mutant phage E gene of the present invention for poultry salmonella is improved by 30-70%. The possibility of bacterial ghost of the poultry salmonella as a candidate vaccine is increased.
In addition to the face-to-face education process currently used at the CHR, this project will develop two modes of eHealth education. Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals. These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information. This allows for the tracking of the type and amounts of diabetes information accessed by participants. Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information. Education mode 2 will be assessed and approved by CHR. Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts). In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team. Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board). New sites and articles will be added on an ongoing basis. Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
PURPOSE:To obtain an active oxygen production increase, containing a pentalene compound as an active ingredient, effective in breaking cancerous cells, etc., and having high safety. CONSTITUTION:An active oxygen production increase containing a compound expressed by the formula [X is -S-, -S(=O)-, -S(=O)2-, -CH2- or -C(CH3)2-] as an active ingredient. Active oxygen is a causative substance for exhibiting toxicity in living bodies. On the other hand, it plays an important role in germicidal, carcinostatic action, enzymic reaction, hormonal action, etc., due to high reactivity thereof. The above-mentioned active oxygen production increaser aims at selectively transferring the compound expressed by the formula to, e.g. only cancerous cells, producing the active oxygen in situ and killing only the cancerous cells. The pharmaceutical is preferably prepared by dissolving the compound expressed by the formula in a vegetable oil, forming the resultant solution, together with soybean phospholipid, etc., into an oil-in-water type microemulsion and providing a fatty emulsion containing the compound expressed by the formula in lipid microspheres.
Participants who express interest in the study will be contacted by telephone. During this phone call, the primary investigator will assess the inclusion/exclusion criteria (i.e., investigators will ask their age, if participants are willing to stay inactive during the required times, refrain from caffeine and food intake within an hour of every visit). Eligible participants will be scheduled for their 1st visit. On the first day of participation in the study, participants will read and sign the informed consent, complete questionnaires, and (to further assess their eligibility for both parts of the study) participants will perform the Montreal Cognitive Assessment, fill out a physical activity questionnaire, and complete a health history form (American College of Sports Medicine). On visit 1 participants will also complete cognitive tasks measuring memory and executive functioning. Investigators will assess resting heart rate by having participants put on a heart rate monitor to record R-R intervals (to assess heart rate variability) at rest for 5 minutes. If participants meet the eligibility requirements assessed on visit 1 (\> 90 mins of physical activity/week) participants will qualify and be scheduled for visits 2 and 3.

During visits 2 and 3, participants will put on a heart rate monitor so that investigators can record their heart rate during the two conditions. Participants will then perform one of two conditions in a counterbalanced order. Participants will either rest for 25 minutes while watching an educational video, do the memory task, complete tasks measuring executive functioning (Stroop color word task, spatial working memory task), and do the recall task; or exercise for 25 min, do the memory task, complete the executive functioning tasks and do the recall task. The memory task is the Auditory Verbal Learning Test (AVLT) which consists of hearing and recalling a list of 15 words (List A) 5 times, hearing and recalling a different list of 15 words (List B), and then recalling List A. Participants will be audio recorded during the memory task to ensure that accurate scoring can be completed. The executive functioning tasks (Stroop, Spatial working memory task) will involve participants responding to stimuli on a computer via a keyboard. The Stroop task requires participants to respond to the color of stimuli that come up on the screen and the Spatial working memory task requires participants to remember the position of varying numbers of dots. The recall task involves participants recalling List A and then being asked to identify from a list of words those that came from List A or List B (recognition). The exercise consists of 5-min of warm-up followed by 20 min of moderate intensity exercise (55-65% heart rate reserve at 60-80 revolutions per minute). All exercise and rest periods will be on a cycle ergometer. During all memory tasks, there will be audio-taping. Subjects will be scheduled with a minimum of 48 hours between Day 1 and Day 2 and between Day 2 and Day 3.
The invention discloses a compound medicine for preventing and treating enteritis of poultry, which contains the following constituents by mass percent: 10-40% of antibiotics, 0.1-1% of obstruent, 2-12% of intestinal mucosa protector, and the balance of auxiliary material. The antibiotics constituent in the compound medicine is one or more of aminoglycosides, polymyxins and berberine hydrochloride. The obstruent is one of scopolamine methobr, atropine, diphenoxylate, loperamide and bismuth subnitrate, or combinations of more. The intestinal mucosa protector is one of vitamin K3, cimetidine and glutamine, or combination of more. The auxiliary material is one of oral glucose, anhydrous glucose, soluble starch, dextrin and cyclodextrin, or combination of more. The invention further discloses a preparation method of the compound medicine for preventing and treating enteritis of poultry.
Patients in this arm were given no intervention. Their self-reported medication adherence was assessed at the baseline (week 0) and follow-up (week 12) visits but during the study period they did not receive any intervention.
Patients in this arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
The rupture of an atherosclerotic plaque cap overlying a lipid pool and/or necrotic core can lead to thrombotic cardiovascular events. In essence, the rupture of the plaque cap is a mechanical event, which occurs when the local stress exceeds the local tissue strength. However, due to inter- and intra-cap heterogeneity, the resulting ultimate cap strength varies, causing proper assessment of the plaque at risk of rupture to be lacking. Important players involved in tissue strength include the load-bearing collagenous matrix, macrophages, as major promoters of extracellular matrix degradation, and microcalcifications, deposits that can exacerbate local stress, increasing tissue propensity for rupture. This review summarizes the role of these components individually in tissue mechanics, along with the interplay between them. We argue that to be able to improve risk assessment, a better understanding of the effect of these individual components, as well as their reciprocal relationships on cap mechanics, is required. Finally, we discuss potential future steps, including a holistic multidisciplinary approach, multifactorial 3D in vitro model systems, and advancements in imaging techniques. The obtained knowledge will ultimately serve as input to help diagnose, prevent, and treat atherosclerotic cap rupture.
The invention relates to acetate anti-alcoholism active liquid. If the active liquid is taken before drinking, capacity for liquor can be increased by 20 to 30 percent. If the active liquid is taken after drinking, the active liquid has effect on anti-alcoholism and sober. So people can feel better about stomach and have clearer mind and ease physically. For patients with gastric diseases (stomach-heat), if patients take the active liquid consistently with right amount, the active liquid can nourish the stomach, treat the stomach and improve digestive function. For the quinquagenarian, if the quinquagenarian takes the active liquid consistently with right amount, the active liquid can soften blood vessel, dilute blood and prevent vascular sclerosis and thrombus.